Edda Spiekerkoetter

Pulmonologist

Assistant Professor of Medicine (Pulmonary and Critical Care Medicine)

Chest Clinic

  • 300 Pasteur Drive
  • Stanford, CA 94305
  • Phone: 650-725-7061
Learn More About the Clinic Getting Here Make An Appointment

Professional Education

Fellowship: Stanford Hospital and Clinics - Critical Care (2009) CA

Fellowship: Stanford University (2008) CA

Fellowship: Lucile Packard Children's Hospital (2006) CA

Residency: Medizinische Hochschule Hannover (2002) Germany

Medical Education: University Hospital Freiburg (1995) Germany

Honors & Awards

Manuscript Award, Cardiovascular Institute at Stanford (Feb 2014)

Poster Award, Excellence Cluster Cardio-Pulmonary System (ECCPS) and Pulmonary Vascular Research Institute (PVRI) (Jan 2014)

Helmholtz International Research Group Award, Helmholtz Zentrum Muenchen, Germany (2013-2016)

Seed Grant- BMP signaling in the RV, Cardiovascular Institute Stanford (2013-2014)

Seed Grant - Phase II Clinical Trial, Wall Center of Pulmonary Vascular Disease (2012-2014)

Seed Grant - Phase II Clinical Trial, SPARK and Spectrum Stanford (2012-2014)

Seed Grant - Small Molecule High Throughout Screen, Wall Center of Pulmonary Vascular Disease (2012)

Winner of Poster competition, Cardiovascular Institute Stanford (Sept 2012)

Supplemental award of the Pulmonary Hypertension Association (PHA), Pulmonary Hypertension Association (2011 - 2016)

Postdoctoral Research Fellowship, Pulmonary Hypertension Association (2003-2005)

K08 Career development award, NIH (2011-2016)

Clinical Trials

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

Reduced BMPR2 expression induces GM-CSF translation and macrophage recruitment in humans and mice to exacerbate pulmonary hypertension
Sawada, H., Saito, T., Nickel, N. P., Alastalo, T.-P., Glotzbach, J. P., & Rabinovitch, M. (2014). Reduced BMPR2 expression induces GM-CSF translation and macrophage recruitment in humans and mice to exacerbate pulmonary hypertension. JOURNAL OF EXPERIMENTAL MEDICINE, 211(2), 263-280.

FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension.
Spiekerkoetter, E., Tian, X., Cai, J., Hopper, R. K., Sudheendra, D., & Rabinovitch, M. (2013). FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension. journal of clinical investigation, 123(8), 3600-3613.

A case of recurrent pericardial constriction presenting with severe pulmonary hypertension.
Brunner, N. W., Ramachandran, K., Kudelko, K. T., Sung, Y. K., Spiekerkoetter, E., & Perez, V. J. (2013). A case of recurrent pericardial constriction presenting with severe pulmonary hypertension. Pulmonary circulation, 3(2), 436-439.

Loss of adenomatous poliposis coli-a3 integrin interaction promotes endothelial apoptosis in mice and humans.
de Jesus Perez, V. A., Yuan, K., Orcholski, M. E., Sawada, H., Zhao, M., & Rabinovitch, M. (2012). Loss of adenomatous poliposis coli-a3 integrin interaction promotes endothelial apoptosis in mice and humans. Circulation research, 111(12), 1551-1564.

Safety and efficacy of transition from systemic prostanoids to inhaled treprostinil in pulmonary arterial hypertension.
de Jesus Perez, V. A., Rosenzweig, E., Rubin, L. J., Poch, D., Bajwa, A., & Zamanian, R. T. (2012). Safety and efficacy of transition from systemic prostanoids to inhaled treprostinil in pulmonary arterial hypertension. American journal of cardiology, 110(10), 1546-1550.

Neutrophil Elastase Is Produced by Pulmonary Artery Smooth Muscle Cells and Is Linked to Neointimal Lesions
Kim, Y.-M., Haghighat, L., Spiekerkoetter, E., Sawada, H., Alvira, C. M., & Rabinovitch, M. (2011). Neutrophil Elastase Is Produced by Pulmonary Artery Smooth Muscle Cells and Is Linked to Neointimal Lesions. AMERICAN JOURNAL OF PATHOLOGY, 179(3), 1560-1572.

BMP promotes motility and represses growth of smooth muscle cells by activation of tandem Wnt pathways
Perez, V. A. J., Ali, Z., Alastalo, T.-P., Ikeno, F., Sawada, H., & Rabinovitch, M. (2011). BMP promotes motility and represses growth of smooth muscle cells by activation of tandem Wnt pathways. JOURNAL OF CELL BIOLOGY, 192(1), 171-188.

S100A4 and Bone Morphogenetic Protein-2 Codependently Induce Vascular Smooth Muscle Cell Migration via Phospho-Extracellular Signal-Regulated Kinase and Chloride Intracellular Channel 4
Spiekerkoetter, E., Guignabert, C., Perez, V. D. J., Alastalo, T.-P., Powers, J. M., & Rabinovitch, M. (2009). S100A4 and Bone Morphogenetic Protein-2 Codependently Induce Vascular Smooth Muscle Cell Migration via Phospho-Extracellular Signal-Regulated Kinase and Chloride Intracellular Channel 4. CIRCULATION RESEARCH, 105(7), 639-U37.

Reactivation of gamma HV68 induces neointimal lesions in pulmonary arteries of S100A4/Mts1-overexpressing mice in association with degradation of elastin
Spiekerkoetter, E., Alvira, C. M., Kim, Y.-M., Bruneau, A., Pricola, K. L., & Rabinovitch, M. (2008). Reactivation of gamma HV68 induces neointimal lesions in pulmonary arteries of S100A4/Mts1-overexpressing mice in association with degradation of elastin. AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 294(2), L276-L289.

Experience with inhaled iloprost and bosentan in portopulmonary hypertension
Hoeper, M. M., Seyfarth, H. J., Hoefflken, G., Wirtz, H., Spielkerkoetter, E., & Halank, M. (2007). Experience with inhaled iloprost and bosentan in portopulmonary hypertension. EUROPEAN RESPIRATORY JOURNAL, 30(6), 1096-1102.

Mts1/S100A4 stimulates human pulmonary artery smooth muscle cell migration through multiple signaling pathways
Spiekerkoetter, E., Lawrie, A., Merklinger, S., Ambartsumian, N., Lukanidin, D., & Rabbiovitch, M. (2005). Mts1/S100A4 stimulates human pulmonary artery smooth muscle cell migration through multiple signaling pathways. CHEST, 128(6), 577S-577S.

Goal-oriented treatment and combination therapy for pulmonary arterial hypertension
Hoeper, M. M., Markevych, I., Spiekerkoetter, E., Welte, T., & Niedermeyer, J. (2005). Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. EUROPEAN RESPIRATORY JOURNAL, 26(5), 858-863.

Increased fibulin-5 and elastin in S100A4/Mts1 mice with pulmonary hypertension
Merklinger, S. L., Wagner, R. A., Spiekerkoetter, E., Hinek, A., Knutsen, R. H., & Rabinovitch, M. (2005). Increased fibulin-5 and elastin in S100A4/Mts1 mice with pulmonary hypertension. CIRCULATION RESEARCH, 97(6), 596-604.

Interdependent serotonin transporter and receptor pathways regulate S100A4/Mts1, a gene associated with pulmonary vascular disease
Lawrie, A., Spiekerkoetter, E., Martinez, E. C., Ambartsumian, N., Sheward, W. J., & Rabinovitch, M. (2005). Interdependent serotonin transporter and receptor pathways regulate S100A4/Mts1, a gene associated with pulmonary vascular disease. CIRCULATION RESEARCH, 97(3), 227-235.

Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids
Hoeper, M. M., Taha, N., Bekjarova, A., Gatzke, R., & Spiekerkoetter, E. (2003). Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. EUROPEAN RESPIRATORY JOURNAL, 22(2), 330-334.

Effects of inhaled salbutamol in primary pulmonary hypertension
Spiekerkoetter, E., Fabel, H., & Hoeper, M. M. (2002). Effects of inhaled salbutamol in primary pulmonary hypertension. EUROPEAN RESPIRATORY JOURNAL, 20(3), 524-528.

Intravenous iloprost for treatment failure of aerosolised iloprost in pulmonary arterial hypertension
Hoeper, M. M., Spiekerkoetter, E., Westerkamp, V., Gatzke, R., & Fabel, H. (2002). Intravenous iloprost for treatment failure of aerosolised iloprost in pulmonary arterial hypertension. EUROPEAN RESPIRATORY JOURNAL, 20(2), 339-343.

[Long-term treatment of primary pulmonary hypertension with inhaled iloprost].
Hoeper, M. M., Schwarze, M., Ehlerding, S., Adler-Schuermeyer, A., Spiekerkoetter, E., & Fabel, H. (2001). [Long-term treatment of primary pulmonary hypertension with inhaled iloprost]. Pneumologie (Stuttgart, Germany), 55(1), 38-43.

Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue.
Hoeper, M. M., Schwarze, M., Ehlerding, S., Adler-Schuermeyer, A., Spiekerkoetter, E., & Fabel, H. (2000). Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. NEW ENGLAND JOURNAL OF MEDICINE, 342(25), 1866-1870.

Prevalence of malignancies after lung transplantation
Spiekerkoetter, E., Krug, N., Hoeper, M., Wiebe, K., Hamm, M., & Fabel, H. (1998). Prevalence of malignancies after lung transplantation. TRANSPLANTATION PROCEEDINGS, 30(4), 1523-1524.